Comparative Pharmacology
Head-to-head clinical analysis: VOYXACT versus XTANDI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VOYXACT versus XTANDI.
VOYXACT vs XTANDI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GABAA receptor positive allosteric modulator; a neuroactive steroid that potentiates GABAergic inhibition.
Androgen receptor inhibitor; binds to the androgen receptor, inhibits nuclear translocation, DNA binding, and transcription of androgen-responsive genes.
Adults: 200 mg orally once daily with food.
160 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life approximately 37 hours (range 24-51 hours), supporting once-daily dosing with steady-state achieved in 5-8 days.
Enzalutamide: 5.8 days; active metabolite N-desmethyl enzalutamide: 7.8-8.6 days. Steady state achieved after ~28 days.
Primarily hepatic metabolism via CYP3A4, with 53% of the dose excreted in feces (mainly as metabolites) and 27% in urine (mostly as metabolites); less than 1% excreted unchanged in urine.
Primarily hepatic metabolism; 77% of dose recovered in feces (as metabolites), 15% in urine (as metabolites); less than 1% excreted unchanged.
Category C
Category C
Antineoplastic
Antineoplastic